Quinolinic acid

別名:pyridine-2,3-dicarboxylic acid, QUIN

Quinolinic Acid (pyridine-2,3-dicarboxylic acid, QUIN), a neuroactive metabolite of the kynurenine pathway, is an agonist of N-methyl-D-aspartate (NMDA) receptor.

Quinolinic acid化学構造

CAS No. 89-00-9

サイズ 価格(税別) 在庫状況
JPY 22000 国内在庫あり
JPY 145500 国内在庫なし(納期7~10日)

代表番号: 045-509-1970|電子メール:[email protected]
よく尋ねられる質問

製品安全説明書

現在のバッチを見る: S362401 DMSO] 25 mg/mL] false] Water] 3 mg/mL] false] Ethanol] Insoluble] false 純度: 99.16%
99.16

Quinolinic acid関連製品

NMDAR阻害剤の選択性比較

生物活性

製品説明 Quinolinic Acid (pyridine-2,3-dicarboxylic acid, QUIN), a neuroactive metabolite of the kynurenine pathway, is an agonist of N-methyl-D-aspartate (NMDA) receptor.
Targets
NMDAR [1]
In Vitro
In vitro QUIN is an agonist of N-methyl-D-aspartate (NMDA) receptor, and it has a high in vivo potency as an excitotoxin. Although QUIN has an uptake system, its neuronal degradation enzyme is rapidly saturated, and the rest of extracellular QUIN can continue stimulating the NMDA receptor. QUIN (10 μM) prevents of glutamate-induced excitotoxicity in primary cultures of rat cerebellar granule neurons, nevertheless mature organotypic cultures of rat corticostriatal system or caudate nucleus chronically exposed to 100 nM QUIN for up to 7 weeks show focal degeneration characterized by the presence of vacuoles in neuropil, swollen dendrites, occasional swollen post-synaptic elements, and degenerated neurons. In vitro QUIN treatment of human primary foetal neurons leads to a substantial increase of tau phosphorylation at multiple positions. The increase in QUIN-induced phosphorylation of tau is attributed to a decrease in the expression and activity of the major tau phosphatases. QUIN can inhibit B monoamine oxidase (MAO-B) in human brain synaptosomal mitochondria and also can be a potent inhibitor of phosphoenolpyruvate carboxykinase (EC 4.1.1.32) from rat liver cytoplasm, an important enzyme in the gluconeogenesis pathway that converts oxaloacetate to phosphoenolpyruvate. QUIN can increase free radical production by inducing NOS activity in astrocytes and neurons, leading to oxidative stress, increasing both poly(ADP-ribose) polymerase (PARP) activity and extracellular lactate dehydrogenase (LDH) activity[1].
In Vivo
In Vivo Quinolinic acid (QUIN), a neuroactive metabolite of the kynurenine pathway, is normally presented in nanomolar concentrations in human brain and cerebrospinal fluid (CSF) and is often implicated in the pathogenesis of a variety of human neurological diseases. The concentration of QUIN varies among different brain regions, with the cerebral cortex containing approximately 1.8 nmol/g wet weight; almost 2-fold than that found in the hippocampus (1 nmol/g wet weight). Intraarterial administration of either micromolar or millimolar concentrations of QUIN results in only negligible accumulations of this metabolite in the brain, suggesting that the central nervous system (CNS) appears to be well protected by the blood brain barrier (BBB) from peripheral QUIN. QUIN can also increase glutamate release and inhibit its reuptake by astrocytes, thus increasing its concentration in the microenvironments, causing neurotoxicity and also limiting glutamate to glutamine recycling in astrocytes by decreasing glutamine synthetase activity. Intrastriatal injection of QUIN provokes a decrease of cellular respiration and ATP levels[1].
動物実験 動物モデル C57Bl/6J mice
投与量 30 nmol
投与経路 Intracerebral injection
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05513807 Not yet recruiting
Delayed Graft Function
Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale France|Centre National de la Recherche Scientifique France
November 2022 Phase 3
NCT05718310 Recruiting
Migraine|Migraine Disorders|Pain
IRCCS National Neurological Institute C. Mondino Foundation|University of Pavia
November 1 2022 Not Applicable
NCT05969990 Recruiting
Migraine in Children
Qilu Hospital of Shandong University
January 1 2022 --
NCT04342975 Completed
AKI
Mayo Clinic|Elysium Health
December 1 2020 Phase 2

化学情報

分子量 167.12 化学式

C7H5NO4

CAS No. 89-00-9 SDF Download Quinolinic acid SDFをダウンロードする
Smiles C1=CC(=C(N=C1)C(=O)O)C(=O)O
保管

In vitro
Batch:

DMSO : 25 mg/mL ( (149.59 mM); 吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Water : 3 mg/mL

Ethanol : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量 濃度 体積 分子量

投与溶液組成計算機(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)

mg/kg g μL

ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)

% DMSO % % Tween 80 % ddH2O
%DMSO %

計算結果:

投与溶媒濃度: mg/ml;

DMSOストック溶液調製方法: mg 試薬を μL DMSOに溶解する(濃度 mg/mL, 注:濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法:Take μL DMSOストック溶液に μL PEG300,を加え、完全溶解後μL Tween 80,を加えて完全溶解させた後 μL ddH2O,を加え完全に溶解させます。

投与溶媒調製方法:μL DMSOストック溶液に μL Corn oil,を加え、完全溶解。

注意:1.ストック溶液に沈殿、混濁などがないことをご確認ください;
2.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください
Tags: Quinolinic acidを買う | Quinolinic acid ic50 | Quinolinic acid供給者 | Quinolinic acidを購入する | Quinolinic acid費用 | Quinolinic acid生産者 | オーダーQuinolinic acid | Quinolinic acid化学構造 | Quinolinic acid分子量 | Quinolinic acid代理店